142 related articles for article (PubMed ID: 35843738)
21. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
23. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract][Full Text] [Related]
24. The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
Perrone E; De Felice F; Capasso I; Distefano E; Lorusso D; Nero C; Arciuolo D; Zannoni GF; Scambia G; Fanfani F
Gynecol Oncol; 2022 Jun; 165(3):585-593. PubMed ID: 35341588
[TBL] [Abstract][Full Text] [Related]
25. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
27. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
Loukovaara M; Pasanen A; Bützow R
Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
[TBL] [Abstract][Full Text] [Related]
28. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
29. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
30. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
31. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
[TBL] [Abstract][Full Text] [Related]
32. [The influence of molecular classification in the selection of postoperative adjuvant therapy in endometrial carcinoma].
Yan XS; Li M; Liang HM; Guo HY; Wu Y; He HJ; Zhang K; Li H
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(32):2500-2505. PubMed ID: 36008320
[No Abstract] [Full Text] [Related]
33. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
34. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
Abdulfatah E; Wakeling E; Sakr S; Al-Obaidy K; Bandyopadhyay S; Morris R; Feldman G; Ali-Fehmi R
Gynecol Oncol; 2019 Sep; 154(3):467-474. PubMed ID: 31248668
[TBL] [Abstract][Full Text] [Related]
35. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
36. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.
Ortoft G; Høgdall C; Hansen ES; Dueholm M
Int J Gynecol Cancer; 2021 Aug; 31(8):1116-1124. PubMed ID: 34112735
[TBL] [Abstract][Full Text] [Related]
38. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
Jamieson A; Huvila J; Thompson EF; Leung S; Chiu D; Lum A; McConechy M; Grondin K; Aguirre-Hernandez R; Salvador S; Kean S; Samouelian V; Gougeon F; Azordegan N; Lytwyn A; Parra-Herran C; Offman S; Gotlieb W; Irving J; Kinloch M; Helpman L; Scott SA; Vicus D; Plante M; Huntsman DG; Gilks CB; Talhouk A; McAlpine JN
Gynecol Oncol; 2022 May; 165(2):201-214. PubMed ID: 35246332
[TBL] [Abstract][Full Text] [Related]
39. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
[TBL] [Abstract][Full Text] [Related]
40. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
